ACCEL Lite: Takeaways from 2021 in Electrophysiology and General Cardiology

FromACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

Start listening View podcast show

ACCEL Lite: Takeaways from 2021 in Electrophysiology and General Cardiology

FromACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ratings:

Length:

28 minutes

Released:

Dec 21, 2021

Format:

Podcast episode

Description

In this interview, Dhanunjaya "DJ" Lakkireddy, MBBS, FACC, Andrew Kates, MD, FACC and Alison L. Bailey, MD FACC, discuss their top takeaways from 2021 in electrophysiology and general Cardiology.

Released:

Dec 21, 2021

Format:

Podcast episode

Titles in the series (100)

The American College of Cardiology offers select interviews and summaries of cardiology’s most interesting research areas from ACCEL’s renowned library, hosted by ACCEL Editor-in-Chief Alison L. Bailey, MD, FACC, FAACPVR.

Skip carousel

ACCEL Lite: Universal Definition of HF Syndrome: Evolving Strategies: The new universal heart failure (HF) definition will be easier for patients and clinicians to understand and will provide standardization across different societies. In this interview, Allen Taylor, MD, FACC; Biykem Bozkurt, MD, PhD, FACC; and... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
11 min listen
ACCEL Lite: STRENGTH Trial: High-Dose Omega-3 Fatty Acids vs. Corn Oil: The benefits and risks of fish oil derivatives remain controversial. STRENGTH (Long-Term Outcomes Study to Assess Statin Residual Risk With Epanova in High Cardiovascular Risk Patients With Hypertriglyceridemia) showed no benefits from administration... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
11 min listen
ACCEL Lite: Rhythm Control vs. Rate Control in Patients With HF and High Burden AF: Atrial fibrillation and heart failure coexist in many patients; what is the best management plan for them? In this interview, Uma Narasimhan Srivatsa, MBBS, FACC; Anthony Tang, MD; and Anthony J. Mazzella, MD, discuss RAFT-AF (A Randomized... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
14 min listen
ACCEL Lite: Primary Prevention and Statins in Adults Over Age 75: Should we deprescribe statins after age 75, or could this commonly used heart medication benefit other conditions of aging? How does cognitive function relate to vascular health, and could statins be useful? In this interview, Annabelle Volgman, MD,... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
9 min listen
ACCEL Lite: The Challenge of Telemedicine: Increasing Utilization Without Robust Data: Telemedicine use has surged over the past year, and this may pose a risk to the quality of care if standards aren't applied to its practice and use. In this interview, Alison Bailey, MD, FACC; Jeff Wessler, MD, MPhil, FACC; and Estefania Oliveros, MD,... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
12 min listen
ACCEL Lite: Low-Flow, Low-Gradient AS: When Is it Severe?: Severe aortic stenosis may go unrecognized, and therefore untreated, in the setting of a low gradient, even if all data point to the existence of a low-flow, low-gradient state and a severe degree of stenosis. In this interview, Mirvat Alasnag, MB,... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
13 min listen
ACCEL Lite: Putting it All Together: Guidelines in the Management of Aortic Stenosis: Explore the timing of aortic valve replacement, the choice between TAVI vs. SAVR, and special considerations in the management of aortic stenosis. In this interview, Catherine Otto, MD, FACC and Uma Narasimhan Srivatsa MBBS, FACC, with Matt A.... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
12 min listen
ACCEL Lite: Should You “Aspirin” in Older Adults With Subclinical Atherosclerosis?: In this interview, Kim Williams MD, MACC; John William “Bill” McEvoy, MB, BCh, MHS; and Michelle Kelsey, MD, discuss whether to use aspirin for primary prevention in adults >70 years old with subclinical atherosclerosis. Like what you hear? Get... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
14 min listen
ACCEL Lite: ACC.21 Late Breaker: The ATLANTIS Trial: The ATLANTIS trial will change the way antithrombotic treatments are chosen after successful transcatheter aortic valve implantation. In this interview, Roxana Mehran, MD, FACC; Jean-Philippe Collet, MD; and Zaid I. Almarzooq, MBBCh, discuss anti-xa... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
14 min listen
ACCEL Lite: Vulnerable Plaques: Vascular Biology Update: The causes of heart attacks are shifting in this era of better control of cholesterol, blood pressure, and smoking and fewer instances of fatty plaque rupturing and causing blood clots. But a different cause of clots seems to be on the rise:... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
13 min listen
ACCEL Lite: Asymptomatic Severe AS; Outcomes of Early Intervention: In this interview, Spencer King III, MD, MACC; Michael Reardon, MD; and Michelle Kelsey, MD, discuss the natural history of asymptomatic severe aortic stenosis and the association of early intervention with outcomes. For 20+ insider interviews like... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
10 min listen
ACCEL Lite: AHA Late-Breaker: DCP – Chlorthalidone Compared to Hydrochlorothiazide for the Prevention of CV Events in Patients with HTN: Thiazides are recommended first line agents for the treatment of hypertension. They have been demonstrated to lower cardiovascular disease. Which thiazide to choose has been a long-standing issue. In this interview, Areef Ishani MD, MS and... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
11 min listen
ACCEL Lite: Takeaways From 2021 in Heart Failure and Preventive Cardiology: In this interview, Clyde W. Yancy, MD, FACC, C. Noel Bairey Merz, MD, FACC and Alison L. Bailey, MD, FACC discuss their top takeaways from 2021 in heart failure and preventive cardiology. These ACCEL Leaders discuss new data regarding SGLT2is, the... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
22 min listen
ACCEL Lite: HRS Late Breaker: LBB-Optimized CRT: In this interview, Andrea Russo, MD, FACC; Marek Jastrzebski, MD, PhD; and Jeffrey Hsu, MD, PhD, focus on a Heart Rhythm Society late-breaking study on LBB optimized CRT, discussing its differences from traditional pacing and benefits to the patient,... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
12 min listen
ACCEL Lite: Are Primary Prevention ICDs Still Valuable in NICM?: Current guidelines recommend implantable cardioverter-defibrillators (ICDs) in nonischemic cardiomyopathy (NICM) among patients with heart failure and ejection fraction ≤35%. Should this change? Should cardiac resynchronization therapy pacemakers be... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
19 min listen
$ACCEL Lite: Are Primary Prevention ICDs Still Valuable in NICM?: Current guidelines recommend implantable cardioverter-defibrillators (ICDs) in nonischemic cardiomyopathy (NICM) among patients with heart failure and ejection fraction ≤35%. Should this change? Should cardiac resynchronization therapy pacemakers be...$
ACCEL Lite: Impact of PCI on Outcomes in Patients With HF: Observational studies suggest a benefit with PCI in patients with HF, but randomized data comparing PCI versus medical therapy or PCI versus coronary artery bypass grafting on outcomes and myocardial recovery are lacking. In this interview, Roxana... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
13 min listen
ACCEL Lite: Innovations in Remote Patient Monitoring: What Can it Bring to My Practice?: Personalizing care in the digital world has always been a challenge because of administrative burden and interoperability issues. The future is already here and we have the chance to leverage remote patient monitoring properly to engage patients with... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
13 min listen
ACCEL Lite: In-Hospital Initiation of Sodium Glucose Cotransporter-2 Inhibitors for Heart Failure with Reduced Ejection Fraction: Failure to initiate an SGLT2i to an eligible HFrEF patient exposes the patient to higher risk of early post-discharge death and readmission, and the real risk that the medication never gets prescribed at all. In this interview, Stephen J. Greene, MD... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
13 min listen
ACCEL Lite: Hypercoagulability in a Nutshell: What Do I Need to Know?: In this interview, Andrea Natale, MD, FACC, and Gregory Piazza, MD, FACC, discuss what you need to know about hypercoagulability in a nutshell. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL. by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
12 min listen
ACCEL Lite: Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL-Cholesterol: After a heart attack, levels of blood lipids such as low-density lipoprotein cholesterol (LDL-C) may influence the risk of further cardiovascular events. In this analysis, we determined that even when LDL-C levels are controlled with a statin,... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
10 min listen
ACCEL Lite: ESC Late Breaker: FIGARO-DKD: Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes: This study investigates the efficacy and safety of finerenone, compared with a placebo to reduce clinically important cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes when added to the standard of care,... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
14 min listen
ACCEL Lite: Omecamtiv Mecarbil and EF in the GALACTIC-HF Trial: In this interview, Michelle O’Donoghue, MD, FACC; John Teerlink, MD, FACC; and Jeffrey Hsu, MD, PhD, discuss the effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in the GALACTIC-HF trial. Like what you... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
13 min listen
$ACCEL Lite: Omecamtiv Mecarbil and EF in the GALACTIC-HF Trial: In this interview, Michelle O’Donoghue, MD, FACC; John Teerlink, MD, FACC; and Jeffrey Hsu, MD, PhD, discuss the effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in the GALACTIC-HF trial. Like what you...$
ACCEL Lite: Pacemaker Patients Undergoing MRI: Many patients will undergo magnetic resonance imaging (MRI) in their lifetimes. It is important to know that, in most cases, it is possible to perform these scans on patients with a pacemaker as long as appropriate precautions are taken. In this... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
13 min listen
ACCEL Lite: Strategies to Maximize Doses and Introduce New Medication: As HF therapy continues to evolve, barriers like medication cost and non-adherence may impede patient care. Pharmacists can overcome these barriers through collaborative practice agreements and patient and provider education. In this interview, Sean... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
11 min listen
ACCEL Lite: ESC Congress 2021 Late Breaker: IAMI: In this interview, Laxmi Mehta, MD, FACC, and Ole Frobert, MD, PhD, and discuss the ESC Congress 2021 late breaker IAMI. This study evaluates whether influenza vaccination improves outcomes in patients with recent MI. Influenza vaccine reduced the... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
10 min listen
ACCEL Lite: Late Breaker: DIAMOND trial: Patiromer For The Management Of Hyperkalemia In Subjects Receiving Renin-angiotensin-aldosterone System Inhibitor Medications For HFrEF: Heart failure patients are generally multi-morbid and at risk for hyperkalemia, which makes treatment with life-saving therapies like RAASi difficult and leads to compromised medical treatment and in turn poor outcomes. This trials showed that with... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
14 min listen
ACCEL Lite: What Should Optimal Medical Therapy Look Like Prior to Intervention?: It is important that patients with reduced heart function are treated with drugs that have been documented to prolong survival. In this interview, Finn Gustafsson, MD, PhD and Michelle Kittleson MD, FACC, along with Michael Mikolaj MD, MPH, FACC,... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
10 min listen
ACCEL Lite: ESC Late Breaker: MASTER DAPT: Dual Antiplatelet Therapy After Coronary Stenting in High Bleeding Risk Patients by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
12 min listen
ACCEL Lite: Pre-Eclampsia: Maternal Red Flag of Risk: Women with preeclampsia and related hypertensive disorders of pregnancy have increased risk of heart disease compared with women who experienced uncomplicated pregnancy. Women should ensure treating clinicians know their reproductive history, and... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
13 min listen
ACCEL Lite: High-Sensitivity Troponin in The ED: Pearls And Pitfalls of Wide-spread Utilization: Use of the newer high-sensitivity troponins offer significant advantages, but with a number of caveats. Although the ability to accelerate the exclusion of myocardial infarction in many patients within just a few hours of ED presentation, the... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
15 min listen

More Episodes from ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

Skip carousel

ACCEL Lite: Optimizing the Care of ASCVD Patients with T2DM: In this interview, Dennis Bruemmer MD, PhD and Alison L. Bailey MD FACC, discuss Optimizing the Care of ASCVD Patients with T2DM. Podcasts | | by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
17 min listen
ACCEL Lite: Revascularization of Stable Ischemic Heart Disease in the Era of COURAGE, ISCHEMIA, and ORBITA: In this interview, David J. Maron MD, FACC and Richard A. Chazal MD, MACC, discuss Revascularization of Stable Ischemic Heart Disease in the Era of COURAGE, ISCHEMIA, and ORBITA. Podcasts | | by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
10 min listen
ACCEL Lite: Long-Term Secondary Prevention After PCI or MI: Aspirin, Clopidogrel, DAPT or DPI?: What are the practical considerations when determining the duration of antiplatelet regimens following PCI? In this interview, Mirvat Alasnag, FACP, FACC, FSCAI, FSCCT, and Sun Moon Kim, MD, FSCAI, FACC, discuss Long-Term Secondary Prevention... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
8 min listen
ACCEL Lite: Understanding the Basics of HF-rEF and Work Up: In this interview, Harriette GC Van Spall MD, MPH, FRCPC, and Clyde W. Yancy MD, MSc, MACC, FAHA, MACP, FHFSA, FASPC (Hon.), discuss the Basics of HF-rEF and Work Up. Podcasts | | by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
12 min listen
ACCEL Lite: ISCHEMIA-EXTENDed – Follow-Up Interim Report: In this interim report of extended follow-up of ISCHEMIA, with a total of 557 deaths (nearly twice the number of deaths in the initial phase), the probability of a survival benefit at 7 years with either initial management strategy was not different.... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
12 min listen
ACCEL Lite: ACC.23 Late-Breaker: Bempedoic Acid and Cardiovascular Outcomes In Statin Intolerant Patients At High Cardiovascular Risk: Statin intolerance is one of the most vexing problems encountered by patients and providers. The CLEAR Outcomes trial directly addresses this problem, using a drug, bempedoic acid, that works only in the liver, thereby reducing the potential for side... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
11 min listen
ACCEL Lite: When Lifestyle Isn't Enough: Surgical vs. Pharmacological Approaches for Obesity: Obesity is a driver of Type 2 diabetes, hypertension, abnormal lipids and is an independent risk factor for cardiovascular events and death. The recent discovery of medications with robust ability to affect appetite is making successful... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
10 min listen
ACCEL Lite: ACC.23 Late-Breaker: Vigorous Exercise in Individuals with Hypertrophic Cardiomyopathy: Primary Results of the LIVE-HCM Study: In this interview, Michael J. Ackerman MD, PhD, and Christopher M. Kramer MD, FACC, with Jeffrey Hsu MD, PhD, discuss ACC.23 Late-Breaker: Vigorous Exercise in Individuals with Hypertrophic Cardiomyopathy: Primary Results of the LIVE-HCM Study. | | by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
10 min listen
ACCEL Lite: Statins To Prevent The Cardiotoxicity From Anthracyclines: The STOP-CA Trial: Patients receiving chemotherapy regimens containing anthracyclines for lymphoma were significantly less likely to show evidence of heart dysfunction after taking atorvastatin for 12 months, according to research from the STOP-CA trial, a... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
13 min listen
ACCEL Lite: From JACC: CACS Improves Risk Prediction in Patients with Suspected Obstructive CAD: Clinicians need more tools to reduce the number of unnecessary tests. Clinical likelihood models represent such tools, and this study demonstrated favorable prognosis for patients who were deferred for testing using the risk factor-weighted clinical... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
8 min listen
ACCEL Lite: PRECISE – Comparison of a Precision Care Strategy with Usual Testing to Guide Management of Stable Patients With Suspected CAD: The PRECISE trial examined how to evaluate patients with chest pain most effectively, minimizing unnecessary testing. In this interview, Pamela S. Douglas MD MACC, FASE, FAHA and Richard A. Chazal MD, MACC discuss PRECISE – Comparison of a... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
12 min listen
ACCEL Lite: IRONMAN – Randomized Trial of Intravenous Ferric Derisomaltose in HFrEF: Iron deficiency is very common in patients with heart failure, affecting between one third to a half of all patients. IRONMAN will help determine if treatment with intravenous iron can help patients feel better, and reduce the risk of being... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
10 min listen
PROMINENT – A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of CVD: In this contemporary population of statin-treated patients with type 2 diabetes and hypertriglyceridemia, 1 in 10 developed a cardiovascular event by 3 years, and despite 20-30% reductions of triglycerides and what we call remnant cholesterol with a... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
8 min listen
ACCEL Lite: AHA Late-Breaker: PROGRESSIVE-AF – The Impact of “First-Line” Rhythm Therapy on Atrial Fibrillation Progression: The drug treatments we use to manage atrial fibrillation don't change the progression in the disease. Catheter ablation, even when performed in younger and healthier patients, modifies the disease trajectory and prevents progression. In this... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
8 min listen
AHA Late-Breaker: OCEAN(a)-DOSE – Reduction of Lipoprotein(a) With Small Interfering RNA: Although lipoprotein(a) is believed to play a causal role in atherogenesis, there are no approved therapies to help lower it. The OCEAN(a) DOSE study examined a drug specifically designed to lower lipoprotein(a) through RNA interference. In this... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
10 min listen
AHA Late-Breaker: EMPA-KIDNEY – Empagliflozin and CV Outcomes in Patients with CKD: Patients with chronic kidney disease are at high risk of worsening kidney disease and cardiovascular events. Treatments that can slow down the worsening of kidney disease and reduce the need for dialysis and kidney transplants and the risk of... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
12 min listen
AHA Late-Breaker: TRANSFORM-HF – Comparative Effectiveness of Torsemide versus Furosemide in Heart Failure: Primary Results: A new study examined a very common clinical question of which loop diuretic or water pill is better in patients living with heart failure - torsemide or furosemide? Prior studies suggested that torsemide might be better than furosemide but they had... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
10 min listen
ACCEL Lite: Top Takeaways from 2022: General Cardiology with Glenn Hirsch MD: In this interview, Glenn A. Hirsch MD, MHS, FACC and Alison L. Bailey MD, FACC discuss Top Takeaways from 2022: General Cardiology. Podcasts | | by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
16 min listen
ACCEL Lite: Top Takeaways from 2022: Preventive Cardiology with Martha Gulati MD: In this interview, Martha Gulati MD MS FACC FAHA FASPC FESC and Alison L. Bailey MD, FACC, discuss the Top Takeaways from 2022: Preventive Cardiology. Podcasts | | by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
15 min listen
ACCEL Lite: Top Takeaways from 2022: Interventional Cardiology with Dipti Itchhaporia MD: In this interview, Dipti Itchhaporia MD, FACC and Alison L. Bailey MD FACC discuss the Top Takeaways from 2022 in Interventional Cardiology. Podcasts | | by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
16 min listen
ACCEL Lite: Top Takeaways from 2022: CV Imaging with Christopher Kramer MD by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
10 min listen
ACCEL Lite: Top Takeaways from 2022: Heart Failure with Clyde Yancy MD: In this interview, Clyde W. Yancy MD, MSc, MACC, FAHA, MACP and Alison L. Bailey MD FACC, discuss the Top Takeaways from 2022: Heart Failure. Dr. Yancy discusses trials including DELIVER, TRANSFORM-HF, DCP, BRIGhtn, and the ACC/AHA/HFSA Guidelines. by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
20 min listen
ACCEL Lite: Improving characterization of Stage A and B HF by adding strain: Earlier detection of people at risk of HF would enable cardioprotection to be initiated earlier and damage avoided. Current imaging tools (eg. ejection fraction) are not sensitive enough to identify early disease. While GLS has been shown to predict... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
16 min listen
$ACCEL Lite: Improving characterization of Stage A and B HF by adding strain: Earlier detection of people at risk of HF would enable cardioprotection to be initiated earlier and damage avoided. Current imaging tools (eg. ejection fraction) are not sensitive enough to identify early disease. While GLS has been shown to predict...$
ACCEL Lite: Real World Implications of 2021 AHA/ACC Chest Pain Guidelines: Modeling of Deferred Testing Recommendations in the PROMISE Trial: In an effort to limit unnecessary testing and increase diagnostic yield, current major guideline recommendations recommend a risk-based strategy with deferred testing in low-risk patients, catheterization in high risk patients, and selective... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
15 min listen
ACCEL Lite: AHA Late-Breaker: DCP – Chlorthalidone Compared to Hydrochlorothiazide for the Prevention of CV Events in Patients with HTN: Thiazides are recommended first line agents for the treatment of hypertension. They have been demonstrated to lower cardiovascular disease. Which thiazide to choose has been a long-standing issue. In this interview, Areef Ishani MD, MS and... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
11 min listen
ACCEL Lite: Routine Ultrasound for Vascular Access: Ultrasound can make it easier for cardiologists to do procedures including angioplasty or stenting when femoral artery is used. In this interview, Sanjit Jolly MD, MSc and Matt Cavender MD MPH, FACC, with Sun Moon Kim MD FSCAI, FACC, discuss Routine... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
14 min listen
ACCEL Lite: From JACC: Exercise for Primary and Secondary Prevention of Cardiovascular Disease: In this interview, Martin Halle MD and Steven E. Nissen MD, MACC discuss a recent piece in JACC: Exercise for Primary and Secondary Prevention of Cardiovascular Disease. Podcasts | | by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
12 min listen
ACCEL Lite: ESC Late-Breaker: eBRAVE-AF: Smartphone-based AF Screening: Any person with a smartphone can screen him- or herself for treatment-relevant atrial fibrillation - the world's most important arrhythmia. This could have huge impact on the prevention of stroke. In this interview, Axel Bauer MD and Thomas F. Deering... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
15 min listen
ACCEL Lite: From JACC: Abbreviated Antiplatelet Therapy after Coronary Stenting in Patients with Myocardial Infarction at High Bleeding Risk: This subgroup analysis from the MASTER-DAPT trial demonstrates that in high-bleeding risk patients with acute or recent myocardial infarction it is safe to stop DAPT 1 month after stenting and that this strategy provides a reduction in bleeding risk.... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
18 min listen
ACCEL Lite: ESC Late-Breaker: DANCAVAS - Screening and Intervention to Prevent Cardiovascular Disease: In the DANCAVAS Trial, researchers found a remarkable reduction in death of any cause, and this might be a game changer in prevention of cardiovascular diseases. In this interview, Axel Cosmus Pyndt Diederichsen MD and Clyde W. Yancy MD, MSc, MACC,... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
14 min listen

Discover this podcast and so much more

ACCEL Lite: Takeaways from 2021 in Electrophysiology and General Cardiology

ACCEL Lite: Takeaways from 2021 in Electrophysiology and General Cardiology

Description

Titles in the series (100)

More Episodes from ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research